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More than 100 years since the outbreak of the 1918 influ-
enza pandemic, we now seem to face another pandemic.
The outbreak of the new coronavirus (SARS-CoV-2)
infection is spreading to every continent, forcing us to live
with this virus for perhaps a long time. Scientists and
clinicians have learned much of coronavirus disease 2019,
COVID-19, and its pathogenesis [1]: not all people exposed
to SARS-CoV-2 are infected and not all infected patients
develop severe respiratory illness. Accordingly, SARS-
CoV-2 infection can be roughly divided into three stages:
stage I, an asymptomatic incubation period with or without
detectable virus; stage II, non-severe symptomatic period
with the presence of virus; stage III, severe respiratory
symptomatic stage with high viral load [2]. From the point
of view of prevention, individuals at stage I, the stealth
carriers, are the least manageable because, at least on some
occasions, they spread the virus unknowingly: indeed, the
first asymptomatic transmission has been reported in Ger-
many [3]. The role of asymptomatic SARS-CoV-2 infected
individuals in disseminating the infection remains to be
defined.
Among over 1000 patients analyzed in Wuhan, except
occasionally in children and adolescence, it infects all the
other age groups evenly. About 15% of the confirmed cases
progress to the severe phase, although there is a higher chance
for patients over 65 to progress into the severe phase [1]. One
of the biggest unanswered questions is why some develop
severe disease, whilst others do not. Clearly, the conventional
wisdom based on overall immunity of the infected patients
cannot explain this broad spectrum in disease presentation.
Two-phase immune responses induced by
COVID-19 infection
Clinically, the immune responses induced by SARS-CoV-2
infection are two phased. During the incubation and non-
severe stages, a specific adaptive immune response is
required to eliminate the virus and to preclude disease
progression to severe stages. Therefore, strategies to boost
immune responses (anti-sera or pegylated IFNα) at this
stage are certainly important. For the development of an
endogenous protective immune response at the incubation
and non-severe stages, the host should be in good general
health and an appropriate genetic background (e.g. HLA)
that elicits specific antiviral immunity. Genetic differences
are well-known to contribute to individual variations in the
immune response to pathogens. However, when a protective
immune response is impaired, virus will propagate and
massive destruction of the affected tissues will occur,
especially in organs that have high ACE2 expression, such
as intestine and kidney. The damaged cells induce innate
inflammation in the lungs that is largely mediated by pro-
inflammatory macrophages and granulocytes. Lung
inflammation is the main cause of life-threatening respira-
tory disorders at the severe stage [4]. Therefore, good
general health may not be advantageous for patients who
have advanced to the severe stage: once severe lung damage
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occurs, efforts should be made to suppress inflammation
and to manage the symptoms.
Alarmingly, after discharge from hospital, some patients
remain/return viral positive and others even relapse. This
indicates that a virus-eliminating immune response to
SARS-CoV-2 may be difficult to induce at least in some
patients and vaccines may not work in these individuals.
Those recovered from the non-severe stage should be
monitored for the virus together with T/B cell responses.
These scenarios should be considered when determining the
strategies of vaccine development. In addition, there are
many types or subtypes of coronavirus. Thus, if vaccines
directly targeting SARS-CoV-2 prove to be difficult to
develop, the Edward Jenner approach should be considered.
Cytokine storm and lung damage
The cytokine release syndrome (CRS) seems to affect patients
with severe conditions. Since lymphocytopenia is often seen in
severe COVID-19 patients, the CRS caused by SARS-CoV-2
virus has to be mediated by leukocytes other than T cells, as in
patients receiving CAR-T therapy; a high WBC-count is
common, suggesting it, in association with lymphocytopenia,
as a differential diagnostic criterion for COVID-19. In any
case, blocking IL-6 may be effective. Blocking IL-1 and TNF
may also benefit patients. Although various clinical sites in
China have announced the use of mesenchymal stromal/stem
cells (MSCs) in severe cases with COVID-19 infection, solid
results have yet to be seen. One caveat is that MSCs need to
be activated by IFNγ to exert their anti-inflammatory effects,
which may be absent in severely affected patients as T cells
are not well activated by SARS-CoV-2 infection. To enhance
effectiveness, one could consider employing the “licensing-
approach”: pretreat MSCs with IFNγ with/without TNF or IL-
1 [5]. Such cytokine-licensed MSCs could be more effective
in the suppression of hyperactive immune response and pro-
motion of tissue repair, as licensed-MSCs are effective in LPS-
induced acute lung damage [6].
Lung damage is a major hurdle to recovery in those severe
patients. Through producing various growth factors, MSCs
may help repair of the damaged lung tissue. It is important
to mention that various studies have shown that in animal
models with bleomycin-induced lung injury, vitamin B3
(niacin or nicotinamide) is highly effective in preventing
lung tissue damage [7]. It might be a wise approach to
supply this food supplement to the COVID-19 patients.
HLA haplotypes and SARS-CoV-2 infection
The major-histocompatibility-complex antigen loci (HLA)
are the prototypical candidates for genetic susceptibility to
infectious diseases [8, 9]. Haplotype HLA-loci variability
results from selective pressure during co-evolution with
pathogens. Immunologists have found that T-cell antigen
receptors, on CD4+ or CD8+ T cells recognize the con-
formational structure of the antigen-binding-grove together
with the associated antigen peptides. Therefore, different
HLA haplotypes are associated with distinct disease sus-
ceptibilities. The repertoire of the HLA molecules com-
posing a haplotype determines the survival during
evolution. Accordingly, it seems advantageous to have
HLA molecules with increased binding specificities to the
SARS-CoV-2 virus peptides on the cell surface of antigen-
presenting cells. Indeed, the susceptibility to various
infectious diseases such as tuberculosis, leprosy, HIV,
hepatitis B, and influenza is associated with specific HLA
haplotypes. Particular murine MHC class II haplotypes are
associated with the susceptibility to influenza. In man, HLA
class I is also associated with H1N1 infections: HLA-A*11,
HLA-B*35, and HLA-DRB1*10 confers susceptibility to
influenza A(H1N1)pdm09 infection [10]. Therefore, it is
imperative to study whether specific HLA loci are asso-
ciated with the development of anti-SARS-CoV-2 immunity
and, if so, to identify the alleles, either class I or II, that
demonstrate induction of protective immunity. Once the
dominant alleles are identified, simple detection kits can be
developed. Such information is critical for (1) strategic
clinical management; (2) evaluation of the efficacy of vac-
cination in different individuals in the general population;
(3) assignment of clinical professional and managerial
teams amid interactions with COVID-19 patients.
Hyaluronan: a potential cause of fatalities
The innate immune response to tissue damage caused by the
virus could lead to acute respiratory distress syndrome
(ARDS), in which respiratory failure is characterized by the
rapid onset of widespread inflammation in the lungs and
subsequent fatality [4]. The symptoms of ARDS patients
include short/rapid breathing, and cyanosis. Severe patients
admitted to intensive care units often require mechanical
ventilators and those unable to breath have to be connected
to extracorporeal membrane oxygenation (ECMO) to sup-
port life [11]. CT images revealed that there are character-
istic white patches called “ground glass”, containing fluid in
the lungs [2]. Recent autopsies have confirmed that the
lungs are filled with clear liquid jelly, much resembling the
lungs of wet drowning [4]. Although the nature of the clear
jelly has yet to be determined, hyaluronan (HA) is asso-
ciated with ARDS [12]; moreover, during SARS infection,
the production and regulation of hyaluronan is defective.
The levels of inflammatory cytokines (IL-1, TNF) are high
in the lungs of COVID-19 patients and these cytokines are
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strong inducers of HA-synthase-2 (HAS2) in CD31+
endothelium, EpCAM+ lung alveolar epithelial cells, and
fibroblasts [13]. Importantly, HA has the ability to absorb
water up to 1000 times its molecular weight. Therefore,
reducing the presence or inhibiting the production of HA
holds a great promise in helping COVID-19 patients
breathe. Doctors can simply provide patients medical grade
hyaluronidase to reduce the accumulation of HA and thus to
clear the jelly in the lung. In animal models, influenza-
induced breathing difficulties can be relieved by intranasal
administration of hyaluronidase. Doctors can also use a
clinically approved bile therapy drug, Hymecromone (4-
Methylumbelliferone, 4-MU), an inhibitor of HAS2 [14].
LPS-induced lung inflammation can be relieved by 4-MU.
4-MU or its chemical derivatives exist widely in various
herbs used in traditional Chinese medicine, which may
explain the observed effectiveness of combined herbal
medicine in some patients.
Overall, this synopsis is based on some clinical common
sense. We propose some simple, but largely ignored,
approaches to the treatment of COVID-19 patients (Fig. 1).
We believe that the two-phase division is very important: the
first immune defense-based protective phase and the second
inflammation-driven damaging phase. Doctors should try to
boost immune responses during the first, while suppressing it
in the second phase. Since Vitamin B3 is highly lung pro-
tective, it should be used as soon as coughing begins. When
breathing difficulty becomes apparent, hyaluronidase can be
used intratracheally and at the same time 4-MU can be given
to inhibit HAS2. Of course, HLA typing will provide sus-
ceptibility information for strategizing prevention, treatment,
vaccination, and clinical approaches. We hope that some of
the above ideas can be employed to help combat this deadly
contagious disease of increasing incidence around the world.
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Fig. 1 Schematic representation of the progression of COVID-19
infection and potential adjuvant interventions. After an incubation
period, the invading COVID-19 virus causes non-severe symptoms
and elicits protective immune responses. The successful elimination of
the infection relies on the health status and the HLA haplotype of the
infected individual. In this period, strategies to boost immune response
can be applied. If the general health status and the HLA haplotype of
the infected individual do not eliminate the virus, the patient then
enters the severe stage, when strong damaging inflammatory response
occurs, especially in the lungs. At this stage, inhibition of hyaluronan
synthase and elimination of hyaluronan can be prescribed. Cytokine
activated mesenchymal stem cells can be used to block inflammation
and promote tissue reparation. Vitamin B3 can be given to patients
starting to have lung CT image abnormalities.
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